Wechsel in der erweiterten Konzernleitung von Roche
27 mai 2024 01h00 HE
|
F. Hoffmann-La Roche Ltd
Basel, 27. Mai 2024 - Roche (SIX: RO, ROG; OTCQX: RHHBY) gab heute bekannt, dass James Sabry (1958), M.D. Ph.D. und Leiter von Roche Pharma Partnering, nach vierzehn Jahren bei Roche in den Ruhestand...
Changes to the Roche Enlarged Corporate Executive Committee
27 mai 2024 01h00 HE
|
F. Hoffmann-La Roche Ltd
Basel, 27 May 2024 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that James Sabry (1958), Head of Roche Pharma Partnering, will be retiring after fourteen years with the company. James Sabry...
Roche granted FDA Breakthrough Device Designation for blood test measuring Lp(a) – a key marker for hereditary cardiovascular risk
22 mai 2024 01h00 HE
|
F. Hoffmann-La Roche Ltd
Approximately one in five people worldwide have elevated Lp(a) levels, putting them at increased risk of cardiovascular diseases including myocardial infarction and stroke.1The Roche Diagnostics...
FDA grants Breakthrough Therapy Designation to Roche’s inavolisib for advanced hormone receptor-positive, HER2-negative breast cancer with a PIK3CA mutation
21 mai 2024 01h00 HE
|
F. Hoffmann-La Roche Ltd
The designation is based on Phase III INAVO120 results, showing the inavolisib-based regimen more than doubled progression-free survival compared with palbociclib and fulvestrant alone in the...
[Ad hoc announcement pursuant to Art. 53 LR] Roche reports positive Phase I results for its dual GLP-1/GIP receptor agonist CT-388 in people with obesity
16 mai 2024 01h00 HE
|
F. Hoffmann-La Roche Ltd
Over 24 weeks, a once-weekly subcutaneous injection of CT-388 achieved a clinically meaningful and statistically significant mean placebo-adjusted weight loss of 18.8% (p < 0.001) At week 24, 100%...
Roche announces FDA approval of one of the first HPV self-collection solutions in the U.S., expanding access and screening options to help eliminate cervical cancer
15 mai 2024 01h00 HE
|
F. Hoffmann-La Roche Ltd
More than half of all U.S. cervical cancer patients are underscreened1, which makes reducing barriers to sample collection and increasing access to screenings crucial to ultimately helping eliminate...
[Ad hoc-Mitteilung gemäss Art. 53 KR] Verkäufe der Roche-Gruppe steigen im ersten Quartal um 2% (CER); beide Divisionen Pharma und Diagnostics wachsen im hohen einstelligen Bereich ohne COVID-19-Produkte
24 avr. 2024 01h00 HE
|
F. Hoffmann-La Roche Ltd
Konzernverkäufe stiegen um 2%1 zu konstanten Wechselkursen (CER; -6% in CHF) dank starkem Wachstum der jüngeren Medikamente und Diagnostika; ohne COVID-19-Produkte nahmen die Konzernverkäufe um 7% zu;...
[Ad hoc announcement pursuant to Art. 53 LR] Roche sales increase by 2% (CER) in first quarter with both divisions growing in high single digit ex COVID-19
24 avr. 2024 01h00 HE
|
F. Hoffmann-La Roche Ltd
Group sales grew by 2%1 at constant exchange rates (CER) (-6% in CHF), driven by the strong growth of newer medicines and diagnostics. Excluding COVID-19-related products, sales increased by 7%. Going...
FDA approves Roche’s Alecensa as the first adjuvant treatment for people with ALK-positive early-stage lung cancer
19 avr. 2024 01h00 HE
|
F. Hoffmann-La Roche Ltd
Approval based on Phase III ALINA study showing Alecensa reduced the risk of disease recurrence or death by an unprecedented 76% in people with ALK-positive early-stage resected non-small cell lung...
Roche’s subcutaneous OCREVUS one-year data demonstrates near-complete suppression of clinical relapses and brain lesions in patients with progressive and relapsing forms of MS
17 avr. 2024 02h00 HE
|
F. Hoffmann-La Roche Ltd
Results from the Phase III study showed that subcutaneous (SC) injection was consistent with IV infusion and demonstrated near-complete suppression of relapse activity (97%) and MRI lesions (97.2%)...